EP Patent

EP2981257A1 — Ingenol mebutate in combination with laser therapy for the treatment of hyperkeratotic skin lesions

Assigned to Leo Laboratories Ltd · Expires 2016-02-10 · 10y expired

What this patent protects

The invention relates to the treatment of actinic keratosis (AK) lesions using laser therapy followed by treatment with ingenol mebutate (e.g., PEP005 Gel).

USPTO Abstract

The invention relates to the treatment of actinic keratosis (AK) lesions using laser therapy followed by treatment with ingenol mebutate (e.g., PEP005 Gel).

Drugs covered by this patent

Patent Metadata

Patent number
EP2981257A1
Jurisdiction
EP
Classification
—
Expires
2016-02-10
Drug substance claim
No
Drug product claim
No
Assignee
Leo Laboratories Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.